Status:
UNKNOWN
ECMO Braile Biomédica® in COVID-19 Patients
Lead Sponsor:
Braile Biomedica Ind. Com. e Repr. Ltda.
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective data collection to evaluate the gas transfer capacity of the Braile Biomédica® OxyPrime® ECMO BRCoating® Membrane Oxygenator in COVID-19 patients during the pandemic.
Detailed Description
Multicenter, retrospective, non-comparative, non-randomized study to assess the clinical performance of the OxyPrime® ECMO BRCoating® Membrane Oxygenator in adult patients with COVID-19
Eligibility Criteria
Inclusion
- Patients ≥ 18 years old, with a previous diagnosis of COVID-19, who were placed on ECMO using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator, from March 2020 to July 2022, following the Instructions for Use (IFU) of the products.
Exclusion
- Patients without a diagnosis of COVID-19
Key Trial Info
Start Date :
September 14 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06086405
Start Date
September 14 2023
End Date
March 1 2024
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Brasília
Lago Sul, Brasília - DF, Brazil, 71681-603